Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report

Cancer Biother Radiopharm. 2006 Apr;21(2):101-5. doi: 10.1089/cbr.2006.21.101.


The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide-yttrium-90-ibritumomab tiuxetan-is described, as well as the subsequent steps taken to both address the occurrence and to prevent the re-occurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Extravasation of Diagnostic and Therapeutic Materials*
  • Humans
  • Male
  • Middle Aged
  • Radiation Injuries / etiology*
  • Radioimmunotherapy / adverse effects
  • Radioimmunotherapy / methods
  • Yttrium Radioisotopes / adverse effects*


  • Antibodies, Monoclonal
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan